Chicago, June 2, 2016 -- Siemens Healthineers -- At the 2016 Annual Meeting of the American Society of Clinical Oncology (ASCO), June 3-7 at McCormick Place in Chicago, Siemens Healthineers exhibits its extensive cancer care portfolio, specifically demonstrating solutions for the complex and increasingly common conditions of lung, liver, prostate, and breast cancers. As a pioneer in bringing innovative technologies to market and enabling physicians to deliver high quality patient care, Siemens Healthineers' portfolio spans laboratory diagnostics, imaging, therapy guidance, clinical IT, and services.

The company's recent acquisition of NEO New Oncology AG, a Cologne, Germany-based company, supports the growth of Siemens Healthineers in the rapidly expanding space for molecular diagnostics in oncology and complements its existing offerings in the German market. NEO New Oncology's liquid biopsy test, "NEOliquid," extracts and sequences circulating free tumor DNA in blood samples, allowing for genomic analysis of the tumor and support of targeted therapy decisions.1

"As enablers of exceptional healthcare, we strive to bring healthcare professionals the solutions needed to diagnose and treat even the most complex of cancers," says David Pacitti, President and Head of Siemens Healthineers North America. "Oncology is a key priority for Siemens, and we are strongly committed to providing unique, leading-edge technology solutions."

Lung

Annual lung cancer screening with computed tomography (CT) for high-risk populations/patients has been shown to contribute to a 20% reduction in lung cancer related mortality.2 Siemens Healthineers offers the industry's most comprehensive approach to low-dose CT lung cancer screening using standard low-dose lung protocols on many of its CT scanners. From the SOMATOM Scope 16-slice CT system to the ultra-premium SOMATOM Force, Siemens Healthineers makes low-dose CT lung cancer screening broadly available to customers.

Liver

Patients with locally advanced primary or secondary liver tumors are often not candidates for surgical resection and in most cases have a limited prognosis. In recent years, interventional procedures such as Selective Internal Radiation Therapy (SIRT, also known as radioembolization) have begun to play a more meaningful role in the treatment of these tumors. SIRT treats liver cancer internally through the injection of millions of SIR-Spheres Y-90 resin microspheres – microscopic resin beads manufactured by Sirtex Medical Limited and labelled with radioactive Yttrium-90 (Y-90) – directly into liver tumors via the hepatic vasculature. These microspheres then become lodged in the tumor's blood vessels, enabling high doses of radiation to be targeted directly to liver tumors while sparing healthy parenchyma.

Siemens Healthineers' advanced imaging technologies, such as its Artis zeego robotic angiography system, guide these types of interventional procedures for precise application of treatment. The protocol known as syngo DynaCT 360, which is specific to the Artis zeego, enables visualization of the full abdomen or thorax -- a feature unique to Siemens Healthineers. The syngo DynaCT 360 protocol helps physicians better visualize large tumors spread throughout the liver, allowing them to more accurately plan the intervention, thereby enhancing procedure safety and confidence. A Saturday, June 4 ASCO Industry Expert Theatre symposium co-hosted by Siemens Healthineers and Sirtex Medical showcases how image guidance plays a key role in the delivery of radioactive microspheres during treatment of liver tumors. Titled "Advanced Imaging for Therapy Management of Selective Internal Radiation Therapy (SIRT) for Non-resectable Primary and Secondary Liver Malignancies," the 60-minute session begins at 9:15 a.m.

Prostate

One in seven men develop prostate cancer at some point during their lifetime.3 In the U.S. alone, one million men undergo a biopsy for the disease each year.4 Conventional diagnosis of prostate cancer typically involves a transrectal biopsy, a painful and invasive procedure. In January, Siemens Healthineers released its noninvasive SEEit prostate magnetic resonance imaging (MR) solution, which enables users of the company's high-performance MAGNETOM Aera 1.5T and MAGNETOM Skyra 3T systems to perform a routine prostate MRI exam in 10 minutes without an endorectal coil. SEEit combines high-density coil technology with unique RESOLVE diffusion technology, which provides physicians with high resolution, low distortion diffusion-weighted imaging (DWI) for accurate depiction of lesions.5

Breast

A recent study involving 22 radiologists demonstrated that all readers improved their accuracy in detecting and diagnosing breast cancers when reading the Siemens 3D digital breast tomosynthesis images in adjunct with full field digital mammography (FFDM/ 2D) versus traditional 2D mammograms. Last year, Siemens Healthineers unveiled its MAMMOMAT Inspiration with Tomosynthesis Option – the breast tomosynthesis add-on option for the company's MAMMOMAT Inspiration digital mammography platform, which in the meantime has been FDA approved for stand-alone use. This breast tomosynthesis algorithm reconstructs multiple 2D images of the breast into a 3D reconstruction to enable detection of tumors hidden by overlapping breast tissue, enabling more accurate diagnosis than standard 2D digital mammography.


For more information, visit: http://usa.healthcare.siemens.com/clinical-specialities/oncology


1 NEOliquid is not commercially available in all countries. Due to regulatory reasons its future availability cannot be guaranteed. Please contact your local Siemens organization for further details.

2 National Lung Screening Trial. Reduced Lung-Cancer Mortality with Low-Dose Computed Tomographic Screening. N Engl J Med;2011:395-409

3 http://seer.cancer.gov/statfacts/html/prost.html

4 Grey A, et al. BJU International 2014; doi: 10.1111/bju.12862

5 Thian YL, et al. Academic Radiology 2014;21:531-7



Siemens AG (Berlin and Munich) is a global technology powerhouse that has stood for engineering excellence, innovation, quality, reliability and internationality for more than 165 years. The company is active in more than 200 countries, focusing on the areas of electrification, automation and digitalization. One of the world's largest producers of energy-efficient, resource-saving technologies, Siemens is No. 1 in offshore wind turbine construction, a leading supplier of gas and steam turbines for power generation, a major provider of power transmission solutions and a pioneer in infrastructure solutions as well as automation, drive and software solutions for industry. The company is also a leading provider of medical imaging equipment – such as computed tomography and magnetic resonance imaging systems – and a leader in laboratory diagnostics as well as clinical IT. In fiscal 2015, which ended on September 30, 2015, Siemens generated revenue of €75.6 billion and net income of €7.4 billion. At the end of September 2015, the company had around 348,000 employees worldwide. Further information is available on the Internet at www.siemens.com.